CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nimutan AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nimutan AB (publ)
Ostra Storgatan 20, 2tr
Phone: +46 36387470p:+46 36387470 JONKOPING, 553 21  Sweden Fax: +46 8222006f:+46 8222006

On 5/10/2023, Nimutan AB (publ) announced its decision to initiate its Voluntary Liquidation.
The Company’s shares have also been delisted from the Nordic SME Sweden marketplace.

Business Summary
Nimutan AB (publ), formerly MedicaNatumin AB is a Sweden-based healthcare products company that develops and manufactures dietary supplements, medical devices and dermatological and cosmetic products. The Company's series consist of documented products in men's and women's health, general health and skin care. The products fall into the categories of dietary supplements, medical technology and dermatological and cosmetic products. The brands include dietary supplements such as L-Argiplex and Nypozin and the scientifically documented skin care series Jabushe. The Company also has the distribution rights for dietary supplements such as Astaxin, Ester-C and Kyolic. Nimutan AB is certified according to Svensk Egenvard's system for safe dietary supplements for consumers.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202212/31/2021Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board JonasCarpvik 54 5/1/2020 5/1/2020
Chief Executive Officer PeterHencz 39 1/1/2022 1/1/2021
Vice Chairman of the Board LarsKaernerud 72 1/1/2020 5/1/2016
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Natumin Pharma AB Snickaregatan 10 HABO SE

Business Names
Business Name
DERMYN®
MCNH MTF
MEDNA
7 additional Business Names available in full report.

General Information
Number of Employees: 63 (As of 12/31/2020)
Outstanding Shares: 375,989,277 (As of 9/30/2022)
Shareholders: 1,904
Stock Exchange: NGM
Fax Number: +46 8222006


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, July 2, 2024